MT Højgaard Holding A/S: Conference call 10 November at 10.00 CET about Q3 2023
MT Højgaard Holding releases its interim report for Q3 2023 on 10 November 2023 and hosts a conference call at 10.00 (CET) that date at which the management will present the results and outlook before answering questions. Registration is not required.
Participants should dial the numbers provided below and enter PIN 531691.
|Denmark||+ 45 78768490|
|UK||+ 44 203-7696819|
|US||+ 1 646-787-0157|
Phone +45 22 70 93 65.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Philips launches ultra lightweight and flexible MR Smart Fit coils to improve radiology productivity and diagnostic confidence at #RSNA2328.11.2023 15:00:00 CET | Press release
November 28, 2023 Amsterdam, the Netherlands and Chicago, USA – RoyalPhilips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today launched three new fit for purpose MR Smart Fit coils at #RSNA23. RF coils are an essential part of every MRI scan. The new ultra-light weight coils provide exceptional flexibility, significant reduction in patient setup time and optimization with Philips’ SmartSpeed AI solution, which allows for better image quality resolution and improved diagnostic confidence for healthcare providers. “Our new Smart Fit coils are an integral part of our patient-centric workflows in MR, with a focus on raising productivity and simplifying workflow,” said Ruud Zwerink, General Manager Magnetic Resonance at Philips. “They combine with our advanced AI-powered software that reduces scanning time and dramatically cuts the number of steps needed to complete an exam. These newly designed coils will help to speed up MR exam process, improving both efficiency and the
Ledende medarbejders transaktioner28.11.2023 14:58:15 CET | pressemeddelelse
Selskabsmeddelelse Nr. 7/2023 København, 28. november 2023 Ledende medarbejders transaktioner Bestyrelsen i Conferize A/S er i dag blevet bekendt med, at 7 investorer har købt 40,26 pct. af selskabets eksisterende aktier fra selskabets 2 hovedaktionærer til en samlet pris på ca. 0,8 mio. kr. – svarende til en pris på 0,01 kr. pr. aktie. Direktør Nicolai Bille Krogh har solgt aktier i Conferize A/S. NAVN:7DREAMS ApSÅRSAG:Nærtstående til Nicolai Bille Krogh, DirektørUDSTEDER:Conferize A/SFONDSKODE:DK0060816148BETEGNELSE:AktierTRANSAKTION:SalgHANDELSDATO:28.11.2023MARKED:Nasdaq First North Growth MarketANTAL STK:40.078.446SALGSSUM DKK:400.784,46 Herudover har Rothausen Development 2016 ApS ejet og kontrolleret af direktør i Suubz ApS, datterselskab i Conferize A/S, solgt aktier i Conferize A/S NAVN:Rothausen Development 2016 ApSÅRSAG:Nærtstående til Claus Andersen, Direktør i datterselskab Suubz ApSUDSTEDER:Conferize A/SFONDSKODE:DK0060816148BETEGNELSE:AktierTRANSAKTION:SalgHANDELSDATO:28
2024 Financial Calendar28.11.2023 14:56:32 CET | Press release
28 November 2023 News Release Pharma Equity Group 2024 Financial Calendar March 4Deadline for shareholder proposals - Annual General meeting March 20 Annual Report 2023 April 16Annual General Meeting May 16Interim Report – for the three-month period ended March 31, 2024 August 16Interim Report – for the six-month period ended June 30, 2024 November 15Interim Report – for the nine-month period ended September 30, 2024 Contact person – Investor Relations On the Company’s website www.pharmaequitygroup.com further information and all published announcements can be found. Inquiries regarding relations with investors and the stock market can be directed to: Thomas Kaas Selsø, CEO, Phone: +45 4022 2114 E-mail: firstname.lastname@example.org. About Pharma Equity Group A/S Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthc
Finanskalender for 202428.11.2023 14:56:32 CET | pressemeddelelse
28. november 2023 Pressemeddelelse Pharma Equity Group Finanskalender for 2024 4. martsFrist for aktionærforslag - Ordinær generalforsamling 20. marts Årsrapport 2023 16. aprilOrdinær generalforsamling 16. majDelårsrapport – for den tremåneders periode, der sluttede 31. marts 2024 16. augustDelårsrapport – for halvåret, der sluttede 30. juni 2024 15. novemberDelårsrapport – for den ni måneders periode, der sluttede 30. september 2024 Kontaktperson – Investor Relations På selskabets hjemmeside www.pharmaequitygroup.com kan yderligere information og alle offentliggjorte meddelelser findes. Henvendelser vedrørende Investor Relations og aktiemarkedet kan rettes til: Thomas Kaas Selsø, CEO, Telefon: +45 4022 2114 E-mail: email@example.com. Om Pharma Equity Group A/S Pharma Equity Group, et børsnoteret selskab på Nasdaq Copenhagen, er fuldt dedikeret til at fremme datterselskabet Reponex Pharmaceuticals A/S' lægemiddelkandidater. Med et urokkeligt fokus på Healthcare er Pharma E
Alternus Energy Reports Third Quarter 2023 Financial Results28.11.2023 14:30:00 CET | Press release
DUBLIN, Ireland, Nov. 28, 2023 (GLOBE NEWSWIRE) -- International Renewable Independent Power Producer (IPP) Alternus Energy Group Plc (OSE: ALT) (the “Company” or “Alternus”) today announced unaudited U.S. GAAP financial results for the third quarter of 2023 under the US GAAP format. Q3 2023 Highlights Power production decreased by 5.4% YoY to 157 MWh due primarily to weather variances in Poland and the Netherlands.Revenue decreased by $1.9 million (15.3%) to $10.5 million compared to the same reporting period last year primarily because of lower electricity pricing in Poland and from lower irradiation levels due to seasonal weather conditions in Poland and the Netherlands.Gross profit increased by $0.5 million (6.4%) to $8.3 million resulting in gross margin of 79.0% as reduced revenues were offset by tightly controlled project operating costs.Selling and general expenses increased by $1 million (41%) YoY as the company grew personnel and infrastructure to drive development activities